Breaking News Instant updates and real-time market news.

FRO

Frontline

$10.85

0.28 (2.65%)

, NAT

Nordic American Tankers

$3.95

-0.05 (-1.25%)

09:04
10/18/19
10/18
09:04
10/18/19
09:04

Frontline, Nordic American Tankers upgraded at Evercore ISI

As previously reported, Evercore ISI analyst Jonathan Chappell upgraded Frontline (FRO) to Outperform from In Line with a $14 price target and upgraded Nordic American Tankers (NAT) to In Line from Underperform. The "eye-watering" spot rates that "turbo-charged" have already pulled back, but are settling above not only pre-spike levels and year-to-date averages, but also ahead of "many of the most bullish estimates on the Street," Chappell tells investors. Fundamental and IMO 2020 improvements are combining to reset the base case for oil tankers just as favorable seasonal factors set in, contends Chappell, who names Euronav NV (EURN), Scorpio Tankers (STNG) and Teekay Tankers (TNK) as his top tanker picks.

FRO

Frontline

$10.85

0.28 (2.65%)

NAT

Nordic American Tankers

$3.95

-0.05 (-1.25%)

EURN

Euronav NV

$11.04

0.345 (3.23%)

STNG

Scorpio Tankers

$35.53

0.29 (0.82%)

TNK

Teekay Tankers

$2.13

0.095 (4.67%)

  • 29

    Oct

FRO Frontline
$10.85

0.28 (2.65%)

09/12/19
BTIG
09/12/19
UPGRADE
BTIG
Buy
Frontline upgraded to Buy from Neutral at BTIG
08/28/19
NORD
08/28/19
UPGRADE
NORD
Buy
Frontline upgraded to Buy from Sell at Nordea
Nordea analyst Axel Styrman double upgraded Frontline to Buy from Sell and raised his price target for the shares to 90 kroner from 50 kroner following the company's Q2 results.
10/18/19
EVER
10/18/19
UPGRADE
Target $14
EVER
Outperform
Frontline upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Jonathan Chappell upgraded Frontline to Outperform from In Line with a $14 price target.
09/12/19
BTIG
09/12/19
UPGRADE
Target $12
BTIG
Buy
Frontline upgraded to Buy from Neutral at BTIG
BTIG analyst Gregory Lewis upgraded Frontline to Buy with a price target of $12, saying that the tanker market looks to be turning the corner after a challenging first half of the year. The analyst believes that tanker rates will trend higher heading into the winter amid increased U.S. exports, slower fleet growth, and the implementation of International Maritime Organisation's 2020 guidelines. Lewis adds that under a backdrop of firmer demand, VLCC rates that spiked over $40k/d in August could move exponentially higher to $60-80k/d.
NAT Nordic American Tankers
$3.95

-0.05 (-1.25%)

10/08/19
10/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Buy from Hold at Jefferies with analyst Brent Thill saying he sees "excellent visibility" with a "clear line of sight into double digit revenue growth for the near future" in the "safest large-cap investment option." 2. ServiceMaster (SERV) upgraded to Outperform from Sector Perform at RBC Capital with analyst Seth Weber citing the findings of his RBC Pest Survey, which showed growing customer satisfaction with Terminix product and which he believes should result in higher customer retention rate. 3. NextEra Energy Partners (NEP) upgraded to Overweight from Equal Weight at Barclays with analyst Moses Sutton saying NextEra Energy's underperformance relative to TerraForm Power (TERP) "has become a compelling opportunity." 4. Nordic American Tankers (NAT) upgraded to Buy from Neutral at BTIG with analyst Gregory Lewis saying tanker rates had undergone a "nuclear winter" over the past 2 years but crude spot rates have finally started to show "tangible" signs of recovery, with Suezmax prices rising to over $70k/d presently from $30k/d last month and $16k/d from 2017 through the first half of 2019. 5. HCP (HCP) upgraded to Overweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/19
BTIG
10/07/19
UPGRADE
Target $4
BTIG
Buy
Nordic American Tankers upgraded to Buy from Neutral at BTIG
BTIG analyst Gregory Lewis upgraded Nordic American Tankers to Buy with a price target of $4. The analyst notes that tanker rates had undergone a "nuclear winter" over the past 2 years, but crude spot rates have finally started to show "tangible" signs of recovery, with Suezmax prices rising to over $70k/d presently from $30k/d last month and $16k/d from 2017 through the first half of 2019. Lewis notes that the price spike has been driven by disruptions from the attacks on Saudi Arabia and the "sanctioning of vessels" by some of the Chinese shipping entities, but he still sees the net cash being generated by higher prices as "real."
10/07/19
BTIG
10/07/19
UPGRADE
BTIG
Buy
Nordic American Tankers upgraded to Buy from Neutral at BTIG
10/18/19
EVER
10/18/19
UPGRADE
EVER
In Line
Nordic American Tankers upgraded to In Line from Underperform at Evercore ISI
EURN Euronav NV
$11.04

0.345 (3.23%)

04/24/19
STFL
04/24/19
NO CHANGE
STFL
U.S. sanctions on Iran could benefit crude tankers, says Stifel
After the U.S. recently said it will re-institute sanctions on Iran on May 1 to now include the eight countries that previously had waivers, Stifel analyst Benjamin Nolan said he believes crude tankers could see a benefit. Nolan noted that much of Iran's oil is moved by their own vessels and the net effect could be increased demand for approximately 30 VLCCs from the trio of Saudi Arabia, Russia, and the UAE, who have said they are willing to fill the void left by absent Iranian barrels. Stocks in the crude tanker group include International Seaways (INSW), TEN, Ltd. (TNP), Scorpio Tankers (STNG), Euronav NV (EURN), DHT Holdings (DHT) and Ardmore Shipping (ASC).
10/16/19
SBSH
10/16/19
NO CHANGE
SBSH
Euronav a good play on spike in tanker spot rates, says Citi
Citi analyst Christian Wetherbee continues to be bullish on the tanker market and he believes Euronav NV is a good way to leverage the recent move higher in spot rates. After the attack on Saudi crude production and COSCO Shipping's sanction concerns, tanker rates have spiked, reaching ~$300,000 per day, Wetherbee tells investors in a research note. He thinks Euronav will likely capture "significant rate upside" beginning in Q3, but mainly in Q4. He keeps a Buy rating on shares of Euronav NV.
02/12/19
02/12/19
UPGRADE

Buy
DNB Markets sees risks discounted in valuation, ups crude tanker stocks to Buy
As previously reported, DNB Markets analyst Nicolay Dyvik upgraded DHT Holdings (DHT), Euronav NV (EURN), Frontline (FRO) and Teekay Tankers (TNK) to Buy from Hold as he believes the risks he put forward in his previous downgrades are now discounted in equity values. At an EV/GAV of 0.8 times, OPEC output cuts are discounted, but IMO 2020 is not, he contended, adding that ship prices are up in the past two months, as the one-year time-charter market starts to discount IMO 2020, and with tanker stocks set to follow.
10/17/19
STFL
10/17/19
UPGRADE
Target $14
STFL
Buy
Euronav NV upgraded to Buy from Hold at Stifel
Stifel analyst Benjamin Nolan upgraded Euronav NV to Buy from Hold with a price target of $14, up from $10.25. The analyst sees a "valuation disparity" between Euronav and the crude tanker peer group. Despite the stock's recent strength, the shares still trade at a 12% discount to net asset value, versus the peer group at a 1% premium, Nolan tells investors in a research note. Further, the analyst expects Euronav's net asset value to grow by 25% through net income over the next six months. He expects the "value gap to close" as IMO 2020 focus fades among investors.
STNG Scorpio Tankers
$35.53

0.29 (0.82%)

05/16/19
05/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Neutral from Sell at Goldman Sachs with analyst Alexandra Walvis saying she sees a more balanced risk/reward in the wake of the stock's recent underperformance. 2. SAIC (SAIC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Edward Caso saying he has "growing comfort" with the company's ongoing integration of its Engility acquisition and sees the deal producing a "notable improvement" in free cash flow. 3. Scorpio Tankers (STNG) upgraded to Overweight from Neutral at JPMorgan with analyst Noah Parquette saying he's seen a considerable increase in interest from investors in the IMO 2020 product tanker story in recent weeks. 4. KB Home (KBH) and Taylor Morrison (TMHC) were upgraded to Outperform from Sector Perform at RBC Capital. 5. MYR Group (MYRG) upgraded to Buy from Hold at Stifel with analyst Noelle Dilts saying she sees "compelling dynamics" in the electric transmission and distribution market as utilities move investment toward power delivery in order to address reliability concerns, the need for grid hardening, and aging infrastructure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/19
STFL
10/17/19
DOWNGRADE
Target $37
STFL
Hold
Scorpio Tankers downgraded to Hold from Buy at Stifel
Stifel analyst Benjamin Nolan downgraded Scorpio Tankers to Hold from Buy with a price target of $37, up from $32. The shares are up 100% year-to-date- on the hope that IMO 2020 would bring much better product tanker charter rates, Nolan tells investors in a research note. While the analyst expects "better days" ahead for the product tanker market, he believes Scorpio Tankers shares now anticipate "at least much of this improvement." He sees less than 10% upside from current stock levels.
07/02/19
BTIG
07/02/19
NO CHANGE
Target $38
BTIG
Buy
Scorpio Tankers price target raised to $38 from $30 at BTIG
BTIG analyst Gregory Lewis raised his price target for Scorpio Tankers to $38 from $30 and reiterated a Buy rating. In a research note to investors, Lewis says he believes it is still the early stages of a cyclical up-cycle in the product tanker market, and says he is "excited" about the potential impact from IMO 2020 on the on the product tanker market in terms of fuel service disruptions, evolving product tanker trade routes and vessel discrimination. The analyst expects the "ripples" of IMO 2020 to be felt for at least the next few years.
06/28/19
JEFF
06/28/19
NO CHANGE
Target $40
JEFF
Buy
Scorpio Tankers a 'very attractive' play on tanker 'super cycle,' says Jefferies
After spending time with management, Jefferies analyst Randy Giveans believes Scorpio Tankers remains well positioned to benefit from a multi-year products tanker market recovery "that is already showing signs of life." The company offers a "very attractive" way to invest in the upcoming products tanker "super cycle" given its "massive" operating leverage to an improving spot market and focus on delevering the balance sheet, Giveans tells investors in a research note. Further, the shares are trading at a 20% discount to net asset value, he adds. The analyst keeps a Buy rating on Scorpio Tankers with a $40 price target.
TNK Teekay Tankers
$2.13

0.095 (4.67%)

02/12/19
DNBM
02/12/19
UPGRADE
DNBM
Buy
Teekay Tankers upgraded to Buy from Hold at DNB Markets
10/02/19
10/02/19
NO CHANGE

Teekay Corp. Investor Day has been postponed
The Investor Day that was to be held in New York on October 2 at 8 am has been postponed.
02/22/19
JPMS
02/22/19
DOWNGRADE
JPMS
Underweight
Teekay Tankers downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Noah Parquette downgraded Teekay Tankers to Underweight following the company's Q4 results.

TODAY'S FREE FLY STORIES

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.